Last reviewed · How we verify
Placebo/dapagliflozin
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels. Used for Type 2 diabetes mellitus, Heart failure with reduced ejection fraction, Chronic kidney disease.
At a glance
| Generic name | Placebo/dapagliflozin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dapagliflozin blocks SGLT2, a transporter protein in the proximal tubule of the kidney that normally reabsorbs filtered glucose back into the bloodstream. By inhibiting this transporter, the drug allows excess glucose to be excreted in the urine, thereby reducing blood glucose concentrations. This mechanism is independent of insulin secretion or action, making it effective across different diabetes phenotypes.
Approved indications
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Hypotension
- Diabetic ketoacidosis
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus (PHASE4)
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome (PHASE2)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes (PHASE4)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |